Herpes simplex viruses (HSVs) usurp the host-cell transcriptional machinery upon infection to promote expression of viral genes 1 . Initial transcription of immediate-early (α) viral genes is activated by the tegument protein VP16 (also termed alpha-gene transactivating factor, α-TIF) 1 . VP16 possesses a potent transactivation domain (TAD) when fused to heterologous DNA-binding domains, and it has been suggested to be prototypic of 'acidic' TADs 2,3 . The molecular mechanism of transcription activation mediated by the VP16 TAD has thus been extensively studied to provide insights into more general mechanisms of gene activation 4 .
a r t i c l e s
Herpes simplex viruses (HSVs) usurp the host-cell transcriptional machinery upon infection to promote expression of viral genes 1 . Initial transcription of immediate-early (α) viral genes is activated by the tegument protein VP16 (also termed alpha-gene transactivating factor, α-TIF) 1 . VP16 possesses a potent transactivation domain (TAD) when fused to heterologous DNA-binding domains, and it has been suggested to be prototypic of 'acidic' TADs 2, 3 . The molecular mechanism of transcription activation mediated by the VP16 TAD has thus been extensively studied to provide insights into more general mechanisms of gene activation 4 .
Previously, we and others identified a large multiprotein complex that is required for transcriptional activation by VP16, as well as for other cellular and viral transcriptional activators, including nuclear receptors, the cholesterol and lipid regulator SREBP, the inflammation and apoptosis regulator NF-κB, adenoviral E1A 13S and the protooncoprotein p53 (refs. 5,6) . This human transcription coactivator complex, which we initially termed activator-recruited cofactor (ARC), mediates activator-dependent recruitment of RNA polymerase II (Pol II) to target genes via binding to the C-terminal domain of the large Pol II subunit 7 (Fig. 1) . It is structurally and functionally related to the Saccharomyces cerevisiae Mediator coactivator 8 , and we therefore refer to it as the Mediator.
It is estimated that the Mediator coactivator complex comprises more than 30 subunits 9 . Growing experimental evidence suggests that many of these individual Mediator subunits can interact with transcriptional activators 10 . Previous studies by us and others indicated that the MED25 subunit (also known as ARC92 and ACID1) is a direct and functionally important target of the VP16 TAD 11, 12 ( Fig. 1) . Notably, residues 402-590 of MED25 show high sequence homology to a repeated sequence in a protein of unknown function, PTOV1, that was previously identified based on its overexpression in prostate tumors 13 ( Supplementary Fig. 1a) . Moreover, deletion mutations showed that this MED25 region functioned as the VP16-binding domain (VBD), suggesting that this conserved sequence may represent a new activator binding motif 12 ( Supplementary  Fig. 1a ). In our previous study, we also found that the N-terminal portion of the VP16 TAD (TADn, Supplementary Fig. 1b ) is critical for strong interaction with MED25, whereas the C-terminal portion only mediated weak binding to MED25 (ref. 12) . On the other hand, the C-terminal domain of the VP16 TAD has been found to recruit the histone acetyltransferases CBP and p300 (ref. 14) . In addition, the C-terminal domain has also been reported to interact with the p62-Tfb1 subunit of TFIIH 15 , with TAF9 (ref. 16 ) and with TFIIA to stimulate assembly of a TFIIA-TFIID-promoter complex 17 . The fulllength VP16 TAD has been further shown to interact with TFIIB 18, 19 and with PC4 (refs. 20, 21) . The latter interaction has been analyzed in detail 22 . Despite these advances, the precise molecular details of how VP16 activates transcription remain unclear.
Here we determined the solution structure of the 19 kDa MED25 VBD (residues 391-553) to consist of a seven-stranded β-barrel flanked by three α-helices. A hydrophobic groove formed by the β-barrel and two of the three α-helices serves as the VP16 TADn binding site. Point mutations targeting this groove prevent the fulllength VP16 TAD from binding to MED25 VBD in vitro and abrogate dominant negative inhibition of VP16 TAD-dependent transcriptional activation by soluble MED25 VBD in cell culture studies.
Results from this study may have important ramifications for both viral and cellular mechanisms of gene activation. First, the newly identified hydrophobic pocket on the surface of MED25 VBD could potentially serve as a new target for small-molecule inhibitors that impinge on MED25-dependent transcriptional activity by viral transactivators of the herpes family. These detailed structure-function studies will also guide future investigations elucidating the geneactivation mechanism of putative cellular transcriptional activators involved in Mediator recruitment through interactions with MED25 and its structurally conserved activator-binding domain.
RESULTS

Structure of MED25 VBD in solution
To obtain mechanistic insights into VP16 TAD-dependent transcriptional activation, we solved the three-dimensional solution structure of the MED25 VBD (amino acids 391-553, Supplementary Fig. 1a ) by NMR spectroscopy. Table 1 lists the statistics of the structure calculations. A summary of a Ramachandran plot generated by PROCHECK 23 is presented in Supplementary Table 1. Supplementary Figure 2 shows a 1 H-15 N HSQC NMR spectrum with assigned peaks of the MED25 VBD. Procedures for sample preparation, data acquisition and structure calculation are described in the Online Methods section. The MED25 VBD shows a seven-stranded β-barrel flanked by three α-helices (Fig. 2a,b) . The structure of the MED25 VBD contains large segments of high internal mobility that primarily localize to variable loops and to the unstructured N-and C termini of the protein (Fig. 2a,b and Supplementary Fig. 3a) . The interior of the β-barrel is tightly packed with aromatic and aliphatic side chains. The barrel is capped by helix α2 on one side and by two adjacent loops at the opposite end of the structure (Fig. 2b and Supplementary Fig. 3b ). Helices α1 and α3 are located on one side of the barrel. The placement of strands β1, β3, β5, the long loop between Glu410 and Leu423, and the C-terminal α3 helix creates a deep furrow that is lined with positively charged residues on both sides and hydrophobic residues at its base (Fig. 2b) . The shape and charge distribution of the furrow, as well as the presence of a central prominent hydrophobic pocket of a size suitable for accommodating a hydrophobic or aromatic side chain, together suggest a potential peptide interaction site. 15 N T 2 relaxation measurements showed a relatively uniform distribution of 15 N T 2 relaxation times of approximately 50-60 ms (Supplementary Fig. 3a) . The N-and C-terminal residues of MED25 VBD and the residues forming the long loop between β1 and β2 show substantially longer 15 N T 2 times, indicating higher local flexibility. Residues 500-508, constituting a loop between β5 and β6, show broad lines of amide resonances, which is most likely a result of local conformational exchange.
Notably, there are only two other human protein domains with considerable sequence homology to the MED25 VBD, both of which are present in PTOV1 (Supplementary Fig. 1a) , a protein of unknown function that is overexpressed in prostate cancer 13 . The high degree of sequence homology suggests that the two PTOV1 domains could indeed undergo similar folding as the MED25 VBD; however, this will need to be experimentally confirmed.
A DALI search 24 identified three domains in the Protein Data Bank that have folds similar to the MED25 VBD ( Fig. 3 and Supplementary  Fig. 4 ). However, they lack sequence homology to the MED25 VBD and have distinct chain topologies. The Spen paralog and ortholog C-terminal (SPOC) domain (PDB ID 1OW1) 25 is found in the Split ends (SPEN) family proteins, which regulate the expression of key transcriptional effectors in diverse signaling pathways. It was reported to mediate interactions with the silencing mediator for retinoid and thyroid receptors (SMRT) and the nuclear receptor co-repressor (NCoR) co-repressors; however, the precise function of this domain is unknown 25 . The other two structural homologs are found in the KU heterodimer (KU70-KU80) (PDB ID 1JEQ 26 ), which is involved in double-stranded DNA repair 26 . Notably, all three structures lack the long C-terminal α3 helix that, together with β3 and β5, forms the hydrophobic pocket in MED25 VBD (Figs. 2 and 3) . As our data discussed below indicate that the MED25 VBD hydrophobic pocket is critical for VP16 binding, this finding suggests that the structural homologs are unlikely to represent VP16 targets.
Molecular mechanism of MED25 VBD-VP16 TADn interaction
We tested two VP16 TAD constructs for binding to MED25 VBD (Supplementary Fig. 1b) . A shorter, 42-residue fragment consisted of the N-terminal portion of the VP16 TAD (amino acids 411-452; 
Hydrogen bonds 90 Fig. 1a ) of the protein. a r t i c l e s a r t i c l e s termed here TADn), and a longer 80-residue fragment contained the full-length TAD (amino acids 411-490; termed here TAD) ( Supplementary Fig. 1b ). Both peptides showed tight binding to MED25 VBD as determined by isothermal titration calorimetric (ITC) assays. The K d of the VP16 TADn-MED25 VBD interaction was 1.6 µM ( Supplementary Fig. 5a ), whereas the full-length VP16 TAD binds to MED25 VBD with a K d of approximately 50 nM ( Supplementary Fig. 5b ). The nanomolar affinity of the full-length VP16 TAD for the MED25 VBD is consistent with the notion that immobilized VP16 TAD can purify the Mediator complex from nuclear extracts in a single step 27 . We mapped the binding site of VP16 TADn on MED25 VBD and the binding site of MED25 VBD on VP16 TADn by NMR spectroscopy (Fig. 4) . 1 H-15 N HSQC spectra of free VP16 TADn and TAD (Fig. 4a , blue signals, and Supplementary Fig. 6a ) showed limited chemical shift dispersion, which is characteristic of unfolded polypeptide chains. In contrast to the free VP16 TADn and TAD, the 1 H-15 N HSQC spectra of the VP16 TADn (Fig. 4a , red signals, and Supplementary Fig. 7 , red signals) and of the full-length TAD (Supplementary Fig. 7 , black signals) in complex with the MED25 VBD showed new far-shifted NMR signals. The broad chemical shift dispersion of those signals indicated that the VP16 TAD adopts a partially folded conformation in the MED25 VBD-bound state. Moreover, a comparison of the spectra of the two bound peptides revealed an unexpected similarity in the far-shifted resonances, which suggested that the partially folded region was located in the TADn. (Fig. 4a, circled signals, and Supplementary Fig. 7 , circled signals). The N-terminal VP16 TAD region was therefore identified as the primary MED25 VBD-binding portion. Consistent with this notion, a previous study showed that MED25-dependent transcriptional activation by the VP16 TAD required an intact TAD N terminus 12 . Based on the above-mentioned results, we used the N-terminal VP16 TAD construct (TADn) for all further NMR experiments and the full-length VP16 TAD (TAD) for pulldown and transcription activation assays.
We obtained sequential backbone assignment of free VP16 TADn by means of standard triple-resonance methods, whereas line broadening prevented us from obtaining continuous backbone resonances assignment of residues Ala434-Gly448 of bound VP16 TADn. In addition to triple-resonance backbone experiments, we used phenylalanine and leucine amino acid-selective labeling and 15 N dispersed NOESY spectra to obtain a nearly complete assignment of bound TADn amide resonances. Only residue Ala438 and Asp443 of bound TADn could not be assigned. Residues D439, D441, F442, L444, D445, L446, M447 and G448 of bound VP16 TADn experience major chemical shift changes upon binding to MED25 VBD (circled peaks in Fig. 4a indicated with assignment and highlighted bars in Fig. 4c ) and may constitute a core binding segment of alternating hydrophobic and negatively charged residues (Supplementary Fig. 1b shows a conserved region in the TADn between Asp437 and Gly448). In addition, Phe442 of the VP16 TADn was shown to be of critical importance for the interaction with the MED25 VBD, as a point mutation of Phe442 to proline prevented binding of the TADn to the VBD 11 .
1 H-15 N HSQC spectra of MED25 VBD showed substantial chemical shift changes upon addition of the VP16 TADn (Fig. 4b) . The complex was in fast to intermediate exchange on the NMR time scale with regard to the dissociation kinetics, and it shuttled among multiple bound conformations, as discussed below. In order to locate the VP16 TADn-binding site on the MED25 VBD, we obtained greater than 90% of the backbone assignment of MED25 VBD bound to VP16 TADn and measured the magnitude of chemical shift changes of the 1 H-15 N HSQC cross peaks upon addition of the VP16 TADn peptide. The values are plotted versus the protein sequence in Fig. 4d . The most prominent chemical shift changes localized to a few discrete regions of the VBD that included residues T424, I449, Q451, I453, S468, C497, C499, L513 and H544. In a structural context, the strongest effects were observed for amino acids in β3 (Fig. 4d,e ) and, to a lesser extent, β1, β5 and helices α1 and α3. Together, these structural elements form a patch of positively charged and hydrophobic residues that are likely to (Fig. 4f) . Indeed, the strongest overall chemical-shift changes upon binding of VP16 TADn were shown by MED25 VBD residues that are situated close to or within this hydrophobic pocket (Fig. 4e,f) . Both proteins showed exchange broadening of NMR resonances in the complex. Upon addition of VP16 TADn, residues Leu449, Gln451 and Ile453 of the MED25 VBD showed line broadening, and residues Arg538-Ile541 could not be assigned at all. On the side of VP16 TADn, residues Val431 to Gly448 showed extensive line broadening upon binding to MED25 VBD, and Ala438 and Asp443 could not be assigned. These observations indicate that there are likely multiple bound conformations. We have previously analyzed a similar situation in detail, in which we experimentally saw both phenomena: simple on-off binding and interaction with multiple bound states 28 .
In addition, we found evidence that the C-terminal portion of the VP16 TAD (TADc) interacts with a portion of MED25 VBD that is opposite on the barrel to the binding site of TADn. By comparing 1 H-15 N HSQC spectra of the MED25 VBD, either bound to the TADn (Supplementary Fig. 8a, red signals) or bound to the fulllength TAD (Supplementary Fig. 8a, black signals) , one can monitor differences in the chemical shift of several amide resonances. Even without assignment of the MED25 VBD while it is bound to the TAD, we could identify five distinct changes in amide chemical shifts and infer their assignment from the MED25 VBD bound to the TADn. We concluded that the observed changes are caused by the interaction of the C-terminal domain of VP16 TAD with MED25 VBD and mapped them to residues Gln456, Val471, Ile521, Gly524 and Leu525 of the VBD. Because Ile521, Gly524 and Leu525 are located on β7 and Val471 is located on β4, the TADc binding site is distinct from the TADn binding site (Supplementary Fig. 8b ). Gln456 is located on α1 and is possibly in contact with a hinge region of TAD. The interaction of TADn with β3 and β5 and the binding of TADc to β4 and β7 result in the VP16 TAD clamping the MED25 VBD.
Point mutants impinge on MED25 VBD-VP16 TAD interaction
Guided by the experimentally observed chemical shift changes on the VBD, we designed ten MED25 VBD point mutants with amino acid substitutions in the VP16 TAD binding site and in areas nearby. Because both positively charged and hydrophobic interactions are thought to contribute to the MED25 VBD-VP16 TAD binding site, we aimed to disrupt the interaction by uniformly replacing all residues with glutamic acid. We screened all mutants in pulldown assays in which lysates from either wild-type or mutant MED25 VBD-expressing HEK293T cells were added to immobilized full-length VP16 TAD. Fractions of bound MED25 VBD protein were then probed by immunoblotting. Only the MED25 VBD Q451E mutant failed to bind to VP16 TAD in vitro, whereas several other mutants (such as K447E, H499E and K545E) showed considerably lower binding than wild-type MED25 VBD (Fig. 5a) . Subsequent NMR analyses confirmed that the Q451E mutant MED25 VBD indeed failed to interact with the VP16 TADn in solution, despite the fact that it remained properly folded (data not shown).
It has been shown previously that overexpressed, soluble MED25 VBD can prevent VP16 TAD-mediated transcriptional activation in a Gal4p-UAS transcription assay in human cells 12 . We therefore tested the four most attenuated binding mutants, K447E, Q451E, H499E and K545E, for their ability to inhibit full-length VP16 TAD-mediated transcription in HEK293T cells. Indeed, as expected from the binding studies, all four MED25 VBD mutants were unable to interfere with Gal4p-VP16 TAD-activated transcription in a dominant negative manner, as compared to wild-type MED25 VBD (Fig. 5b) . Mutant and wild-type MED25 VBD showed a comparable level of expression when transfected into HEK293T cells (Supplementary Fig. 9 ). 400  405  530  552  545  540  535  525  520  515  510  505  500  495  490  485  480  475  470  465  460  455  450  445  440  435  430  425  420  415  410 (Fig. 4e). a r t i c l e s NMR titrations of the unlabeled Q451E mutant MED25 VBD and 15 N-labeled VP16 TADn showed features of a remnant, substantially reduced interaction. Although minor chemical-shift changes were observed, all of the broadly dispersed resonances, characteristic of the partial folding transition of VP16, were absent (compare right and middle panels of Fig. 5c ). We conclude that Q451E, sitting at the center of the hypothetical VP16 TADn binding site, greatly compromised the ability of MED25 VBD to interact with the viral peptide, both in vitro and in vivo.
DISCUSSION
The human Mediator coactivator complex is recruited by a number of viral and cellular transcription factors 10 . Previous studies by the authors and others have shown that the herpes simplex viral transactivator VP16 targets the Mediator by interacting with the MED25 subunit, and deletion mutagenesis has demonstrated that the MED25 VP16-binding domain is able to inhibit VP16-mediated transcriptional activation in vivo 11, 12 . Our studies described here reveal the structure of the MED25 VBD and provide critical molecular details of the VP16 TAD-MED25 VBD interface. Our results also define an extended hydrophobic furrow on the MED25 VBD that is lined with positively charged residues, and we present evidence that amino acids located in this furrow play a key role in VP16 TAD binding and VP16 TAD-dependent transcriptional activation. Indeed, our results show that a single MED25 VBD mutation (Q451E) located in a central hydrophobic pocket within the furrow prevents binding to the VP16 TAD in vitro and abolishes the dominant negative inhibition of MED25 VBD on VP16 TAD-dependent transcriptional activation in cellular contexts.
Although several other entries in the Protein Data Bank (such as the SPOC domain of SPEN and the two β-barrel structures of the KU70-KU80 heterodimer) show superficial structural homology to the MED25 VBD (Fig. 3) , they present different folding topologies and lack the long C-terminal helix α3. Because α3 together with β3 and β5 form part of the hydrophobic VP16-binding pocket, these differences suggest that the MED25 VBD represents a structurally and functionally distinct domain and that these other proteins are unlikely targets of VP16 or other viral transactivators of the herpes family.
Multiple sequence alignments indicate that residues in the hydrophobic pocket are well conserved among the N-and C-terminal domains of PTOV1 and MED25 VBD (Supplementary Fig. 1a ).
Although we have previously shown that the VP16 TAD does not associate with PTOV1 when expressed in cells 12 , our structural studies of MED25 VBD and its extensive conservation with the two PTOV1 domains suggest that PTOV1 could indeed represent a target for both viral and cellular transcription factors. Because PTOV1 was first identified as a putative prostate cancer oncogene 13 , it is tempting to speculate that PTOV1 (and the MED25 VBD-related domains) may play a role as a target for cellular activators in gene regulatory pathways contributing to prostate cancer proliferation.
The VP16 TADn peptide adopts a folded conformation upon binding to MED25 VBD, while retaining a certain degree of flexibility. We conclude from titration experiments that VP16 TADn samples two or more conformations in the bound state, consistent with an 'induced fit' type of interaction. This intrinsically unfolded structure of the unliganded state of the VP16 TADn may allow a multitude of interactions with transcriptional targets. Indeed, whereas a single bound state may provide the tightest association, strong interaction with one partner might prevent binding to additional coactivator partners (for example, CBP-p300), impeding efficient transactivation. Accordingly, as shown in previous studies, the VP16 TAD interacts with a number of targets in the basal transcription machinery, including TFIIB 18, 19 , TFIIA 17 , the TFIID subunit TAF II 31 (ref. 16 ) and the Tfb1 subunit of TFIIH 15 .
Notably, other viral activators of the herpes family also employ MED25 and its VP16-binding domain as their transcription regulatory conduit. Indeed, both the varicella-zoster virus IE62 protein and the Kaposi's sarcoma-associated herpesvirus LANA-1 protein target MED25 (refs. 29,30) , and IE62 was shown to directly interact with the same region of MED25 as VP16 (ref. 31) . Taken together with the findings presented here, as well as those of previous studies by the authors and others 11, 12 , these results indicate that MED25 and the VP16-binding domain could serve a critical role in transactivation of viral genes in the herpes family of viruses, and the molecular interface of viral activators and MED25 might thus provide a new target for the development of antiviral therapeutics.
Viruses commonly mimic, or hijack, cellular mechanisms for their maturation and propagation. It is therefore likely that cellular transactivators also target MED25 and the VP16-binding domain that we have structurally defined here for transcriptional regulation. In this a r t i c l e s regard, it is noteworthy that MED25 has been implicated in CharcotMarie-Tooth neuropathy 32 , in which it has been suggested to play an as yet poorly understood pathophysiological role in gene activation.
In conclusion, our study has revealed intricate structural and mechanistic details of the gene activation mechanism of the benchmark activator VP16 that might guide future investigations of transactivation mechanisms of both viral and cellular activators. These studies could also provide insights and tools to design new therapeutic strategies that target the molecular underpinning of viral transactivation that is essential to propagation of herpes family viruses.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
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